AOD-9604

AOD-9604 Research Peptide (HGH Fragment 177-191)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses

AOD-9604 (Tyr-hGH Fragment 177-191, CAS 221231-10-3) is a synthetic 16 amino acid peptide fragment corresponding to the C-terminal lipolytic domain of human growth hormone (amino acids 177–191), with a stabilizing tyrosine residue added at the N-terminus, supplied by Nextday Peptides for laboratory and analytical research applications. Originally developed by Metabolic Pharmaceuticals Ltd. in Australia during the 1990s, AOD-9604 was engineered to isolate hGH’s lipolytic domain for focused metabolic research without activating the full growth hormone receptor pathway. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.

Compound Specifications

Why Research Laboratories Select AOD-9604

AOD-9604 is one of the most studied synthetic hGH fragment peptides in current metabolic and adipocyte biology research. Its unique design — isolating the C-terminal lipolytic domain of hGH while adding a stabilizing N-terminal tyrosine — makes it a valuable tool for laboratories investigating lipid metabolism pathways, adipocyte signaling, and receptor-independent lipolytic mechanisms independently of full growth hormone receptor activation or IGF-1 pathway engagement.

• Synthetic 16 amino acid hGH C-terminal fragment — derived from amino acids 177–191 of human growth hormone
• N-terminal tyrosine modification — enhances structural stability compared to the native hGH 176-191 fragment
• Does not activate the full growth hormone receptor — studied for receptor-independent lipolytic pathway interactions
• Does not elevate IGF-1 in preclinical models — useful for studies requiring metabolic pathway isolation without growth axis activation
• Studied in preclinical rodent models examining adipocyte lipolysis, lipogenesis inhibition, and fat oxidation pathways
• Advanced through six human clinical trials involving over 900 participants — extensive published literature available
• Lyophilized format ensures stability and reproducibility across experimental runs
• Batch and lot identifiers on all labeling for full laboratory documentation compliance

Research Background

AOD-9604 was first developed in the early 1990s when researchers identified that the C-terminal region of human growth hormone (amino acids 176–191) was responsible for much of the hormone’s lipolytic activity. Metabolic Pharmaceuticals Ltd. modified this fragment with a stabilizing N-terminal tyrosine to create AOD-9604. Heffernan et al. (2009) and Ng et al. (2010) published preclinical findings on AOD-9604’s lipolytic and lipogenesis-inhibiting properties in rodent adipocyte models. The compound advanced through Phase I and Phase II clinical trials but was discontinued in 2007 after failing to achieve statistical significance in its largest Phase IIb study. It has no regulatory approval from any major health authority. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.

Reference sources: PubChem — AOD-9604 (CID 71300630)

Shipping & Fulfillment

• Ships from U.S. warehouses — Florida, North Carolina, and California
• Overnight and 2-day shipping available at checkout
• Same-day processing on orders placed before 3:30 PM ET
• Discreet packaging with full tracking provided
• Bulk research orders welcome — contact us for volume pricing

Storage & Handling

• Store lyophilized peptide at -20°C away from light and moisture
• After reconstitution store at 2–8°C and use within 14 days
• Avoid repeated freeze-thaw cycles to maintain integrity
• Handle using appropriate laboratory safety protocols
• Keep containers sealed when not in use

Frequently Asked Questions

For Research Use Only — Not for human or veterinary consumption • Not evaluated by the FDA • Supplied by Nextday Peptides for laboratory research applications only